Apellis Pharmaceuticals, Inc. (APLS)
May 14, 2026 - APLS was delisted (reason: acquired by BIIB)
41.03
-0.03 (-0.07%)
Inactive · Last trade price on May 13, 2026
Apellis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,105 | 1,004 | 781.37 | 396.59 | 75.42 | 66.56 | |
Revenue Growth | 42.46% | 28.46% | 97.02% | 425.83% | 13.31% | -73.44% |
Cost of Revenue | 394.82 | 398.09 | 445.29 | 412.9 | 392.87 | 426.07 |
Gross Profit | 710.47 | 605.69 | 336.07 | -16.31 | -317.45 | -359.51 |
Selling, General & Admin | 545.24 | 550.27 | 501.05 | 500.82 | 277.16 | 176.77 |
Operating Expenses | 545.24 | 550.27 | 501.05 | 500.82 | 277.16 | 176.77 |
Operating Income | 165.22 | 55.43 | -164.98 | -517.12 | -594.61 | -536.28 |
Interest Expense | -43.6 | -44.33 | -40.39 | -29.58 | -32.63 | -13.24 |
Interest & Investment Income | 13.4 | 13.14 | 12.77 | 20.93 | 8.91 | 0.42 |
Other Non Operating Income (Expenses) | 0.12 | -0.13 | -2.17 | -0.73 | -0.29 | -96.31 |
EBT Excluding Unusual Items | 135.15 | 24.11 | -194.77 | -526.5 | -618.61 | -645.41 |
Other Unusual Items | - | - | -1.95 | - | -32.89 | -100.59 |
Pretax Income | 135.15 | 24.11 | -196.72 | -526.5 | -651.5 | -746 |
Income Tax Expense | 1.88 | 1.72 | 1.16 | 2.13 | 0.67 | 0.35 |
Net Income | 133.27 | 22.39 | -197.88 | -528.63 | -652.17 | -746.35 |
Net Income to Common | 133.27 | 22.39 | -197.88 | -528.63 | -652.17 | -746.35 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 127 | 126 | 124 | 119 | 106 | 84 |
Shares Outstanding (Diluted) | 131 | 130 | 124 | 119 | 106 | 84 |
Shares Change | 5.48% | 4.80% | 4.40% | 11.84% | 25.70% | 12.32% |
EPS (Basic) | 1.05 | 0.18 | -1.60 | -4.45 | -6.15 | -8.84 |
EPS (Diluted) | 1.03 | 0.17 | -1.60 | -4.45 | -6.15 | -8.84 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 37.47 | 45.01 | -88.27 | -595.51 | -515.27 | -564.23 |
Free Cash Flow Per Share | 0.28 | 0.35 | -0.71 | -5.02 | -4.86 | -6.68 |
Gross Margin | 64.28% | 60.34% | 43.01% | -4.11% | - | - |
Operating Margin | 14.95% | 5.52% | -21.11% | -130.39% | -788.38% | -805.67% |
Profit Margin | 12.06% | 2.23% | -25.32% | -133.29% | -864.70% | -1121.28% |
Free Cash Flow Margin | 3.39% | 4.48% | -11.30% | -150.16% | -683.18% | -847.66% |
EBITDA | 166.63 | 56.99 | -163.18 | -515.34 | -593.06 | -534.9 |
EBITDA Margin | 15.07% | 5.68% | -20.88% | -129.94% | - | - |
D&A For EBITDA | 1.4 | 1.56 | 1.8 | 1.78 | 1.55 | 1.38 |
EBIT | 165.22 | 55.43 | -164.98 | -517.12 | -594.61 | -536.28 |
EBIT Margin | 14.95% | 5.52% | -21.11% | -130.39% | - | - |
Effective Tax Rate | 1.39% | 7.14% | - | - | - | - |
Revenue as Reported | 1,105 | 1,004 | 781.37 | 396.59 | 75.42 | 66.56 |